The Experts below are selected from a list of 306 Experts worldwide ranked by ideXlab platform
Hsinyun Sun - One of the best experts on this subject based on the ideXlab platform.
-
Cutaneous Cryptococcosis in solid organ transplant recipients
Medical Mycology, 2010Co-Authors: Francoise Dromer, Olivier Lortholary, Hsinyun Sun, Barbara D Alexander, Graeme N Forrest, Marshall G Lyon, Jyoti Somani, Krishan Lal GuptaAbstract:Clinical manifestations, treatment, and outcomes of Cutaneous Cryptococcosis in solid organ transplant (SOT) recipients are not fully defined. In a prospective cohort comprising 146 SOT recipients with Cryptococcosis, we describe the presentation, antifungal therapy, and outcome of Cutaneous cryptococcal disease. Cutaneous Cryptococcosis was documented in 26/146 (17.8%) of the patients and manifested as nodular/mass (34.8%), maculopapule (30.4%), ulcer/pustule/abscess (30.4%), and cellulitis (30.4%) with 65.2% of the skin lesions occurred in the lower extremities. Localized disease developed in 30.8% (8/26), and disseminated disease in 69.2% (18/26) with involvement of the central nervous system (88.9%, 16/18), lung (33.3%, 6/18), or fungemia (55.6%, 10/18). Fluconazole (37.5%) was employed most often for localized and lipid formulations of amphotericin B (61.1%) for disseminated disease. Overall mortality at 90 days was 15.4% (4/26) with 16.7% in disseminated and 12.5% in localized disease (P = 0.78). SO...
Igor Čuček - One of the best experts on this subject based on the ideXlab platform.
-
Primary Cutaneous Cryptococcosis in a renal transplant recipient: case report
Mycoses, 2009Co-Authors: Jerneja Videčnik Zorman, Tatjana Lejko Zupanc, Zlatko Parač, Igor ČučekAbstract:We report a kidney transplant recipient with severe skin- and soft-tissue infection mimicking necrotising fasciitis. Patient failed to respond to empirical antibiotic therapy for presumed bacterial cellulitis. Culture of aspirate from the wound and tissue samples revealed Cryptococcus neoformans. No signs of systemic cryptococcal infection were found. After antifungal treatment and surgical intervention, complete healing was achieved. Clinical and microbiological characteristics of this patient are discussed. Our case indicates that primary Cutaneous Cryptococcosis must be included in the differential diagnosis of severe cellulitis in solid organ transplant recipients not responding to broad-spectrum antibiotic regimens. In our case, prompt diagnosis and treatment could dramatically modify the outcome.
Yann Le Meur - One of the best experts on this subject based on the ideXlab platform.
-
Intracranial granuloma and skull osteolysis: complication of a primary Cutaneous Cryptococcosis in a kidney transplant recipient.
American Journal of Kidney Diseases, 2005Co-Authors: Jean-philippe Rerolle, Jean-christophe Szelag, Mirela Diaconita, François Paraf, Jean-claude Aldigier, Yann Le MeurAbstract:Cryptococcosis is the third most common invasive fungal infection in organ transplant recipients after candidiasis and aspergillosis. It occurs almost exclusively in the late posttransplantation period (>6 months after the initiation of immunosuppression). Subclinical onset of meningitis is the usual clinical presentation. Despite initiation of therapy, the mortality rate associated with this infection in this patient population remains high. To the best of our knowledge, this report describes one of the first cases of a rare entity: a primary Cutaneous Cryptococcosis in a renal transplant recipient disclosed by skull osteomyelitis and pseudotumoral intracranial extension. Surgical debridement and azole antifungal therapy were performed. Ten months after the onset of treatment, the patient feels good, clinical examination findings are normal, and no sign of evolutive Cryptococcosis is noted.
Krishan Lal Gupta - One of the best experts on this subject based on the ideXlab platform.
-
Cutaneous Cryptococcosis in solid organ transplant recipients
Medical Mycology, 2010Co-Authors: Francoise Dromer, Olivier Lortholary, Hsinyun Sun, Barbara D Alexander, Graeme N Forrest, Marshall G Lyon, Jyoti Somani, Krishan Lal GuptaAbstract:Clinical manifestations, treatment, and outcomes of Cutaneous Cryptococcosis in solid organ transplant (SOT) recipients are not fully defined. In a prospective cohort comprising 146 SOT recipients with Cryptococcosis, we describe the presentation, antifungal therapy, and outcome of Cutaneous cryptococcal disease. Cutaneous Cryptococcosis was documented in 26/146 (17.8%) of the patients and manifested as nodular/mass (34.8%), maculopapule (30.4%), ulcer/pustule/abscess (30.4%), and cellulitis (30.4%) with 65.2% of the skin lesions occurred in the lower extremities. Localized disease developed in 30.8% (8/26), and disseminated disease in 69.2% (18/26) with involvement of the central nervous system (88.9%, 16/18), lung (33.3%, 6/18), or fungemia (55.6%, 10/18). Fluconazole (37.5%) was employed most often for localized and lipid formulations of amphotericin B (61.1%) for disseminated disease. Overall mortality at 90 days was 15.4% (4/26) with 16.7% in disseminated and 12.5% in localized disease (P = 0.78). SO...
Graeme N Forrest - One of the best experts on this subject based on the ideXlab platform.
-
Cutaneous Cryptococcosis in solid organ transplant recipients
Medical Mycology, 2010Co-Authors: Francoise Dromer, Olivier Lortholary, Hsinyun Sun, Barbara D Alexander, Graeme N Forrest, Marshall G Lyon, Jyoti Somani, Krishan Lal GuptaAbstract:Clinical manifestations, treatment, and outcomes of Cutaneous Cryptococcosis in solid organ transplant (SOT) recipients are not fully defined. In a prospective cohort comprising 146 SOT recipients with Cryptococcosis, we describe the presentation, antifungal therapy, and outcome of Cutaneous cryptococcal disease. Cutaneous Cryptococcosis was documented in 26/146 (17.8%) of the patients and manifested as nodular/mass (34.8%), maculopapule (30.4%), ulcer/pustule/abscess (30.4%), and cellulitis (30.4%) with 65.2% of the skin lesions occurred in the lower extremities. Localized disease developed in 30.8% (8/26), and disseminated disease in 69.2% (18/26) with involvement of the central nervous system (88.9%, 16/18), lung (33.3%, 6/18), or fungemia (55.6%, 10/18). Fluconazole (37.5%) was employed most often for localized and lipid formulations of amphotericin B (61.1%) for disseminated disease. Overall mortality at 90 days was 15.4% (4/26) with 16.7% in disseminated and 12.5% in localized disease (P = 0.78). SO...
